JAVI Pharma Expertise Ltd 09517807 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is pharma consultancy. Digita Accounts Production Advanced 6.30.9574.0 true 09517807 2022-04-01 2023-03-31 09517807 2023-03-31 09517807 2 2023-03-31 09517807 core:CurrentFinancialInstruments 2023-03-31 09517807 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 09517807 core:OfficeEquipment 2023-03-31 09517807 1 2023-03-31 09517807 bus:SmallEntities 2022-04-01 2023-03-31 09517807 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 09517807 bus:FullAccounts 2022-04-01 2023-03-31 09517807 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 09517807 bus:RegisteredOffice 2022-04-01 2023-03-31 09517807 bus:CompanySecretary1 2022-04-01 2023-03-31 09517807 bus:Director2 2022-04-01 2023-03-31 09517807 bus:Director3 2022-04-01 2023-03-31 09517807 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 09517807 core:OfficeEquipment 2022-04-01 2023-03-31 09517807 countries:EnglandWales 2022-04-01 2023-03-31 09517807 1 2022-04-01 2023-03-31 09517807 2022-03-31 09517807 core:OfficeEquipment 2022-03-31 09517807 1 2022-03-31 09517807 2021-04-01 2022-03-31 09517807 2022-03-31 09517807 2 2022-03-31 09517807 core:CurrentFinancialInstruments 2022-03-31 09517807 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 09517807 core:OfficeEquipment 2022-03-31 09517807 1 2022-03-31 09517807 1 2021-04-01 2022-03-31 09517807 1 2021-03-31 iso4217:GBP xbrli:pure

Registration number: 09517807

JAVI Pharma Expertise Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2023

 

JAVI Pharma Expertise Ltd

Contents
for the Year Ended 31 March 2023

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

JAVI Pharma Expertise Ltd

Company Information
for the Year Ended 31 March 2023

Directors

Mr Delaere

Mrs Duwelz-Church

Company secretary

Windsor Accountancy Limited

Registered office

St Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU

Registered number

09517807 ( England and Wales )

Accountants

Windsor Accountancy Ltd
Chartered Certified Accountants
St. Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU

 

JAVI Pharma Expertise Ltd

(Registration number: 09517807)
Balance Sheet as at 31 March 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

59

758

Current assets

 

Debtors

5

2,000

-

Cash at bank and in hand

 

7,663

18,271

 

9,663

18,271

Creditors: Amounts falling due within one year

6

(5,290)

(5,368)

Net current assets

 

4,373

12,903

Net assets

 

4,432

13,661

Capital and reserves

 

Called up share capital

100

100

Retained earnings

4,332

13,561

Shareholders' funds

 

4,432

13,661

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 4 July 2023 and signed on its behalf by:
 

.........................................
Mr Delaere
Director

 

JAVI Pharma Expertise Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
St Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU

These financial statements were authorised for issue by the Board on 4 July 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

JAVI Pharma Expertise Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Computer Equipment

50% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2022 - 2).

 

JAVI Pharma Expertise Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 April 2022

3,498

3,498

At 31 March 2023

3,498

3,498

Depreciation

At 1 April 2022

2,740

2,740

Charge for the year

699

699

At 31 March 2023

3,439

3,439

Carrying amount

At 31 March 2023

59

59

At 31 March 2022

758

758

5

Debtors

Note

2023
£

2022
£

Income tax asset

2,000

-

 

2,000

-

6

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

Taxation and social security

-

2,989

Accruals and deferred income

973

973

Other creditors

4,317

1,406

5,290

5,368

 

JAVI Pharma Expertise Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

7

Related party transactions

Transactions with directors

2023

At 1 April 2022
£

Advances to director
£

Repayments by director
£

At 31 March 2023
£

Advances and credits

(1,405)

6,500

(9,412)

(4,317)

         
       

 

2022

At 1 April 2021
£

Advances to director
£

Repayments by director
£

At 31 March 2022
£

Advances and credits

(9,745)

17,484

(9,144)

(1,405)

         
       

 

Other transactions with directors

The balance due to the directors at the year end date was free of interest and deemed repayable on demand.